Vistagen Therapeutics, Inc. (VTGN)

4.6600 +0.0400 (+0.87%) 收市：04:00PM EDT

Vistagen Therapeutics, Inc.

343 Allerton Avenue
South San Francisco, CA 94080
United States
650 577 3600
https://www.vistagen.com

版塊: Healthcare
行業: Biotechnology
全職員工: 37

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Shawn K. Singh J.D.	CEO & Director	947.92k	無	1963
Ms. Cynthia Lynn Anderson CPA	Chief Financial Officer	391.2k	無	1969
Mr. Joshua S. Prince M.B.A.	Chief Operating Officer	568.44k	無	1971
Mr. Reid G. Adler Esq., J.D.	Chief Corporate Development Officer & General Counsel	675k	無	1955
Mr. Mark Adrian McPartland	Senior Vice President of Investor Relations	300k	無	1966
Ms. Trisha Fitzmaurice	Senior Vice President of Human Resources	無	無	無
Dr. Allen Easley Cato III, M.D., Ph.D.	Senior Vice President of Development Operations	無	無	無
Dr. Mark J. Ginski Ph.D.	Senior VP and Head of Chemistry, Manufacturing & Controls	無	無	1972
Mr. Mark Flather	Senior Vice President of Corporate Strategy & Capital Markets	無	無	無
Dr. Erik Berglund M.D., Ph.D.	Senior VP of Global Regulatory Affairs & Pharmacovigilance	無	無	無

截止 2024年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

公司管治

截至 無 止，Vistagen Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。